NMC-G1Homo sapiens (Human)Cancer cell line

Also known as: National Medical Center-Glioma 1, NMCG1, NMCG-1

🤖 AI SummaryBased on 7 publications

Quick Overview

Human glioma cell line with potential for cancer research.

Detailed Summary

The NMC-G1 cell line is derived from a human glioma, specifically an astrocytoma of grade III. It is used in cancer research to study the molecular mechanisms of glioma progression and therapeutic responses. The cell line has been utilized in studies involving genomic profiling, drug sensitivity, and the identification of genetic alterations associated with cancer development. Research on NMC-G1 has contributed to understanding the role of specific genes and pathways in glioma biology, including the identification of mutations and copy number variations that may influence tumor behavior and treatment outcomes. This cell line is part of larger studies aimed at improving cancer treatment strategies through targeted therapies and personalized medicine approaches.

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1608
Species	Homo sapiens (Human)
Tissue Source	Brain[UBERON:UBERON_0000955]

Donor Information

Age Category	Unknown
Sex	Female

Disease Information

Disease	Astrocytoma
Lineage	CNS/Brain
Subtype	Glioblastoma
OncoTree Code	GB

DepMap Information

Source Type	HSRRB
Source ID	ACH-000200_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	BRAF	p.Val600Glu (c.1799T>A)	Unspecified	-	PubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

11,13

D16S539

10,13

D5S818

D7S820

8,12

TH01

9,9.3

TPOX

8,9

vWA

17,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas.

Aoyagi M., Ohno K., Imoto I., Inazawa J.

Cancer Sci. 96:676-683(2005).

DOI PubMed PMC

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

DOI PubMed

Novel secretory heparin-binding factors from human glioma cells (glia-activating factors) involved in glial cell growth. Purification and biological properties.

Kurokawa T.

J. Biol. Chem. 268:2857-2864(1993).

DOI PubMed

Measuring the effect of PDGF on fibroblasts using glioma cell lines.";

Shinoura N., Kondo T., Yoshioka M.

(In book chapter) Biological aspects of brain tumors. Proceedings of the 8th Nikko brain tumor conference, Karatsu (Saga) 1990; Tabuchi K. (eds.); pp.235-243; Springer; Tokyo; Japan (1991).

DOI